Tucson, AZ, September 09, 2021 –(PR.com)– NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer.Continue reading
Category Archives: AZBio News
INanoBio Announces Successful Development of Novel Nanopore Transistor Prototype, a Step Towards Ultra-Fast DNA Sequencing
INanoBio Makes Strides Towards Ubiquitous Point-of-Need DNA Sequencing
Breaking Down Data Siloes: New Analytics Platform Sparks Opportunity for Rare Disease Field
C-Path, NORD and FDA have spent two years building the platform set to launch
Sept. 14 at the 2021 RDCA-DAP Workshop.Continue reading
Which Industry is the Leading Investor In U.S. R & D?
According to the 2021 PhRMA member annual survey, PhRMA member companies invested $91.1 billion in R&D, the highest level of investment on record. The U.S. biopharmaceutical sector at large accounts for roughly one-sixth of total domestic R&D spending by U.S. businesses, the single largest share of all U.S. business R&D. Continue reading
BD Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results
- BD Veritor™ At-Home COVID-19 Test is Over-the-Counter, Rapid Antigen Test Using Scanwell Health Mobile App to Deliver Reliable Results in 15 Minutes
- Digitally Read Test Provides Clear Positive or Negative Confirmation of COVID-19 StatusContinue reading
Like Venom Coursing Through the Body: Researchers Identify Mechanism Driving COVID-19 Mortality
Researchers have identified what may be the key molecular mechanism responsible for COVID-19 mortality – an enzyme related to neurotoxins found in rattlesnake venom.
Regenesis Biomedical Expands Expert Medical Advisory Board
Board Will Guide Evidence Development for Clinical Outcomes and Health EconomicsContinue reading
FDA Approves First COVID-19 Vaccine
Approval Signifies Key Achievement for Public Health
UArizona Researchers Develop Regenerative, Safe Therapeutic for Alzheimer’s Disease
Developed in the University of Arizona Health Sciences Center for Innovation in Brain Science, the therapy has been licensed to startup NeuTherapeutics Inc.
Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
- Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1
- Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy.
- Roche/GSK collaboration represents an important step towards a personalised healthcare strategy for certain solid tumour patients.